{
  "docId": "019de073-8568-725b-9a17-a64262808fc8",
  "docSlug": "d872feff7a8967ecac479e446ba0e3da",
  "documentTitle": "Context Therapeutics | Investor Presentation Deck | 25 slides",
  "authorId": "context-therapeutics",
  "authorName": "Context Therapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-09-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 19,
  "pageCount": 25,
  "prevPage": 18,
  "nextPage": 20,
  "slideType": "solution",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 3,
  "notes": "The charts show dose-response curves where the proprietary antibodies (IM301, IM302) maintain high binding to CLDN6 while showing minimal off-target binding compared to the benchmark.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de073-8568-725b-9a17-a64262808fc8/19",
  "deckHref": "/decks/019de073-8568-725b-9a17-a64262808fc8",
  "deckJsonHref": "/decks/019de073-8568-725b-9a17-a64262808fc8.json",
  "deckAnchorHref": "/decks/019de073-8568-725b-9a17-a64262808fc8#slide-19",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.64,
        "y": 0.45
      },
      "kind": "chart",
      "text": "IM302 binding curves",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3bba0566-cc35-4153-9b73-f06a6b42b70d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.12,
        "y": 0.45
      },
      "kind": "chart",
      "text": "Benchmark binding curves",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4573fa9d-465d-49fc-bc9f-f3b2efc70bd9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.25,
        "x": 0.38,
        "y": 0.45
      },
      "kind": "chart",
      "text": "IM301 binding curves",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ff3a4b69-e8df-46ef-8a1f-7d6601492379",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.5,
        "x": 0.25,
        "y": 0.4
      },
      "kind": "legend",
      "text": "CLDN6, CLDN9, CLDN3, CLDN4",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "42b1bc82-9379-467a-a4d9-a70fab4f8954",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.05,
        "y": 0.14
      },
      "kind": "list",
      "text": "Benchmark (IMAB027) exhibits off-target binding to CLDN9\n1st generation Context mAb (IM301, IM302) exhibit high CLDN6 selectivity\n2nd generation Context mAb (data not shown) exhibit even greater CLDN6 selectivity than IM301 and IM302",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3e93e2a0-7625-4547-a7d9-653fe7a457ad",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.05,
        "y": 0.07
      },
      "kind": "title",
      "text": "Our Antibodies Display High Selectivity for CLDN6",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "19c93dc1-d6c4-4984-8a7f-a7ab2397b005",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "2x2 matrix",
      "slug": "matrix-2x2",
      "agent": null,
      "layer": "slide",
      "matchId": "b5727131-e36e-4157-814b-a50ac7125713",
      "evidence": "legend: CLDN6, CLDN9, CLDN3, CLDN4",
      "confidence": 0.5
    },
    {
      "name": "Chart Selection Guide",
      "slug": "chart-selection-guide",
      "agent": "Designer",
      "layer": "slide",
      "matchId": "70be06b6-7692-49f7-9c42-eee3ef380cc3",
      "evidence": "chart/line: Benchmark binding curves",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 24,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "6f563f0a-bba6-40be-8cea-242e5c29e44d",
      "evidence": "Slides 11-24 outline the potential of ONA-XR and CLDN6xCD3 Bispecific Antibody Program",
      "position": 0,
      "objective": "Highlight the benefits of investment in Context Therapeutics",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.7,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}